Seven Grand Managers’s SAB Biotherapeutics SABS Stock Holding History

Seven Grand Managers’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-275,000	Closed	-$1.05M	–	209
2026 Q1	$1.05M	Buy	+275,000	New	+$1.1M	0.07%	144

Other funds holding SABS

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Seven Grand Managers's SABS Position: Q2 2026 in Review

Seven Grand Managers sold out of SAB Biotherapeutics (SABS) in Q2 2026, closing a stake of 275,000 shares — an estimated $1.05M sold.

Seven Grand Managers first reported a position in SABS in Q1 2026 and held it in 1 quarter. The position peaked at $1.05M in Q1 2026. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

Seven Grand Managers reported no remaining SAB Biotherapeutics position as of Q2 2026 after selling out during the quarter.
Seven Grand Managers sold 275,000 SAB Biotherapeutics shares in Q2 2026, an estimated $1.05M.
Seven Grand Managers first reported a position in SAB Biotherapeutics in Q1 2026 and held it in 1 quarter.
Seven Grand Managers's SAB Biotherapeutics position peaked at $1.05M in Q1 2026.
87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Seven Grand Managers's 13F filing for Q2 2026, filed 14 Aug 2026.